US Capitol Capsule: Manufacturing incentives, R&D credit at heart of Obama tax fix
This article was originally published in Scrip
With almost lightening speed, criticism about the Obama administration's plan to overhaul the US tax system without raising the deficit began flying around Washington within moments of the document's 22 February release – mostly for the framework's lack of details. But one proposal included in the plan drew immediate praise: Expanding, simplifying and making permanent the research and experimentation tax credit – commonly called the R&D tax credit – in which the biopharmaceutical industry stands to benefit.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.